[go: up one dir, main page]

FR2601591B1 - Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci - Google Patents

Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci

Info

Publication number
FR2601591B1
FR2601591B1 FR878710156A FR8710156A FR2601591B1 FR 2601591 B1 FR2601591 B1 FR 2601591B1 FR 878710156 A FR878710156 A FR 878710156A FR 8710156 A FR8710156 A FR 8710156A FR 2601591 B1 FR2601591 B1 FR 2601591B1
Authority
FR
France
Prior art keywords
granulocyta
production
pharmaceutical preparation
preparation containing
stable pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878710156A
Other languages
English (en)
Other versions
FR2601591A1 (fr
Inventor
Minoru Machida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of FR2601591A1 publication Critical patent/FR2601591A1/fr
Application granted granted Critical
Publication of FR2601591B1 publication Critical patent/FR2601591B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR878710156A 1986-07-18 1987-07-17 Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci Expired - Lifetime FR2601591B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948786 1986-07-18
JP16948886 1986-07-18
JP16948686 1986-07-18
JP16948986 1986-07-18

Publications (2)

Publication Number Publication Date
FR2601591A1 FR2601591A1 (fr) 1988-01-22
FR2601591B1 true FR2601591B1 (fr) 1991-04-26

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
FR878710156A Expired - Lifetime FR2601591B1 (fr) 1986-07-18 1987-07-17 Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci

Country Status (24)

Country Link
KR (1) KR930004597B1 (fr)
CN (1) CN1033738C (fr)
AT (1) AT402259B (fr)
AU (1) AU611856B2 (fr)
BE (1) BE1000253A3 (fr)
CA (1) CA1297007C (fr)
CH (1) CH671157A5 (fr)
DE (1) DE3723781C2 (fr)
DK (1) DK171308B1 (fr)
ES (1) ES2010226A6 (fr)
FR (1) FR2601591B1 (fr)
GB (1) GB2193631B (fr)
GR (1) GR871067B (fr)
HK (1) HK64893A (fr)
HU (1) HU198627B (fr)
IE (1) IE60290B1 (fr)
IL (1) IL83220A (fr)
IT (1) IT1218927B (fr)
NL (1) NL192917C (fr)
NO (1) NO171828C (fr)
PT (1) PT85343B (fr)
SE (1) SE503312C2 (fr)
SG (1) SG64393G (fr)
YU (1) YU47543B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0459516A1 (fr) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Formes d'administration orale de protéines biologiquement actifs
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (fr) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Système thérapeutique pour l'administration parentérale de facteurs de croissance hématopoietiques
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP3895109B2 (ja) * 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2001077137A1 (fr) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Proteines de fusion d'albumine
EP1232753B1 (fr) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Solution de protéine stable contenue dans des récipients à base de résine hydrophobe et procédé de stabilisation associé
DK1129720T3 (da) * 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
EP1260230A4 (fr) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd Preparations stabilisees a long terme
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277889B1 (fr) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Protéines chimériques d'albumine et interféron beta
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
EP1594530A4 (fr) 2003-01-22 2006-10-11 Human Genome Sciences Inc Proteines hybrides d'albumine
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
WO2010092571A2 (fr) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Peptides courts dérivés de bêta-défensine
CN102740840A (zh) * 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
EP2399572A1 (fr) 2010-06-22 2011-12-28 Sandoz AG Stockage à long terme de G-CSF humain recombinant non glycosylé
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
WO2018138267A1 (fr) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Procede de determination de l'efficacite d'une composition comprenant le g-csf
ES2986389T3 (es) * 2018-05-21 2024-11-11 Chugai Pharmaceutical Co Ltd Formulación liofilizada sellada en un vial de vidrio

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
AU523077B2 (en) * 1978-03-20 1982-07-08 Green Cross Corporation, The Hgi glycoprotein
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
AU590543B2 (en) * 1985-02-05 1989-11-09 Albert Einstein College Of Medicine Of Yeshiva University Purification of native colony stimulating factor-1
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
NO171828C (no) 1993-05-12
SE503312C2 (sv) 1996-05-13
CH671157A5 (de) 1989-08-15
HUT44941A (en) 1988-05-30
GB8716904D0 (en) 1987-08-26
YU47543B (sh) 1995-10-03
IE60290B1 (en) 1994-06-29
PT85343B (pt) 1990-04-30
SG64393G (en) 1993-08-06
BE1000253A3 (fr) 1988-09-27
IT8767594A0 (it) 1987-07-10
IL83220A (en) 1993-01-31
IE871933L (en) 1988-01-18
DE3723781C2 (de) 1999-09-02
GB2193631B (en) 1990-11-21
NO872966D0 (no) 1987-07-16
YU134287A (en) 1989-06-30
HU198627B (en) 1989-11-28
CA1297007C (fr) 1992-03-10
ATA177587A (de) 1996-08-15
GR871067B (en) 1987-11-19
AU611856B2 (en) 1991-06-27
DE3723781A1 (de) 1988-01-21
DK171308B1 (da) 1996-09-02
AU7566587A (en) 1988-01-21
CN1033738C (zh) 1997-01-08
CN87104963A (zh) 1988-02-24
GB2193631A (en) 1988-02-17
NL192917C (nl) 1998-05-07
DK368387A (da) 1988-01-19
IT1218927B (it) 1990-04-24
PT85343A (en) 1987-08-01
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
AT402259B (de) 1997-03-25
NL8701640A (nl) 1988-02-16
NO171828B (no) 1993-02-01
IL83220A0 (en) 1987-12-31
SE8702907L (sv) 1988-01-19
NL192917B (nl) 1998-01-05
KR930004597B1 (ko) 1993-06-01
DK368387D0 (da) 1987-07-15
KR880001297A (ko) 1988-04-22
FR2601591A1 (fr) 1988-01-22
SE8702907D0 (sv) 1987-07-17
NO872966L (no) 1988-01-19

Similar Documents

Publication Publication Date Title
FR2601591B1 (fr) Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci
FR2565101B1 (fr) Granule contenant une substance physiologiquement active, procede pour le preparer et son utilisation
FR2581871B1 (fr) Solutions a base de phenytoine, leur procede de preparation et leur application pharmaceutique
FR2501204B1 (fr) Derives d'un acide quinoleine-carboxylique, procede pour les preparer et medicament en contenant
DE3683664D1 (de) Pharmazeutisches tablettierverfahren.
IL82213A0 (en) Composition for stimulating chondrocytes and osteoblasts(ossein hydroxy-apatite compound),method for its production and pharmaceutical products containing said composition
EP0290915A3 (en) Flavone-3-carboxylic-acid compounds, and process, intermediates for their preparation and medicines containing these compounds
FR2558829B1 (fr) Isomeres de l'hydroxyvitamine d2, composition pharmaceutique et procede de preparation
FR2578865B1 (fr) Procede pour la preparation de solutions d'un materiau ligno-cellulosique et solutions obtenues.
FR2518091B1 (fr) 23-dehydro-25-hydroxyvitamine d3, son procede de preparation et composition pharmaceutique la renfermant
FR2616434B1 (fr) Composes de carboxymethyle, procede pour les preparer et medicament les contenant
FI884455A7 (fi) Reniiniä estäviä dipeptidejä, menetelmä niiden valmistamiseksi, niitä sisältäviä lääkkeitä ja näiden käyttö.
FR2510571B1 (fr) Spirothiazolidinedione, son procede de production et preparation pharmaceutique la contenant
FR2543546B1 (fr) Derives de gonadoreline contenant un groupe b-aspartyle, procede pour leur preparation et preparations pharmaceutiques les contenant
BE894597A (fr) Nouvelles xanthines a activite pharmacologique, leur procede d'obtention, les compositions pharmaceutiques les contenant et leur utilisation en medecine humaine
FR2580649B1 (fr) (-) - 1b - ethyl - 1a - hydroxymethyl -1,2,3,4,6,7,12,12ba-octahydroindolo(2,3-a) quinolizine, procede pour la preparer et compositions pharmaceutiques contenant celle-ci
FR2558828B1 (fr) " 1a,25-dihydroxy-22z-deshydrovitamine d " composition pharmaceutique et procede de preparation
FR2621918B1 (fr) 2',3'-didesoxy-4-thio-uridines, procede de preparation de ces substances et medicaments qui en contiennent
FR2586681B1 (fr) Derives du methylene-dioxy-phenanthrene et du stilbene, procede pour leur preparation et medicaments les contenant
HUT47849A (en) Process for producing new pharmaceutical with analgetic and hypertonicity-relaxing effect
FR2599037B1 (fr) Dihydrogeno-1,3 disilazanes fonctionnels et procede pour leur preparation
AR242193A1 (es) Procedimiento para la preparacion de 4-/4,5-dihidro-2-imidazolil(o 2-oxazolil o 2-tiazolil)7-amino-5(o 3,5)-halogeno benzamida e intermediarios de sintesis utilizados segun dicho procedimiento.
FR2551753B2 (fr) Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant
FR2583040B1 (fr) Procede pour la production de 2,6-naphtalenediol et de 2,6-diacetoxynaphtalene
FR2605318B1 (fr) Procede de preparation d'azetidinones.